Project Grant R43AG062075

This federal Project Grant award, with funding of $143,829 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), aims to establish human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) as robust models for studying how intrinsic circadian regulation impacts cardiomyocyte size and function. The award also seeks to determine if mutations affecting cardiomyocyte size and function also disrupt cardiomyocyte clock...

The National Institute on Aging (NIA) awarded a $1,931,965 Project Grant (CFDA 93.866 - Aging Research) to Regenerative Research Foundation to develop and validate a novel human induced pluripotent stem cell (iPSC) model that incorporates cerebrovascular interactions for studying Alzheimer's disease-related dementias (ADRD). The project aims to generate a 3D human cell model that integrates cerebral cortical neurons, glia, vascular endothelial cells, pericytes, and microglia to improve the...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will fund the development of a 3D bioprinted heart tube model to study how aberrant biomechanical forces impede cardiac proliferation in Hypoplastic Left Heart Syndrome (HLHS). The total funding amount is $148,548, awarded to the Research Institute at Nationwide Children's Hospital (RINCH), a prominent non-profit research organization. The project...

This federal Project Grant award of $167,400 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to elucidate the mechanical and metabolic pathways underlying hypertrophic cardiomyopathy caused by MYBPC3 gene mutations. The principal investigator, Dr. Joshua Meisner, will develop novel mouse and induced pluripotent stem cell models to study the progression of this severe, pediatric-onset form of...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $299,781 to Mogling Bio Inc. to develop a first-in-class therapeutic regimen that attenuates aging of human hematopoietic stem cells (HSCs). The central hypothesis is that targeting CDC42 activity with the drug CASIN can restore CDC42-regulated polarity and rejuvenate aged human HSCs ex vivo, which could benefit bone marrow HSC transplant...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $631,261 to Rutgers, The State University of New Jersey to conduct research on the role of autophagy and mitochondrial quality control mechanisms in cardiac senescence. The key goals are to elucidate how aging-induced suppression of autophagy promotes senescence in cardiomyocytes, and to investigate the involvement of YAP activation and...

This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $2,249,307 to support research aimed at understanding and overcoming the immaturity of pluripotent stem cell-derived cardiomyocytes (PSC-CMs). The project seeks to identify critical gene regulatory networks underlying the premature arrest of PSC-CM maturation, with the goal of developing transcriptome-based strategies to improve the...

This $162,540 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to elucidate the mechanism by which aging exacerbates defects in cell quality control and metabolism, disrupting alveolar epithelial type II (AT2) progenitor cell function and enhancing aberrant transitional cell accumulation in pulmonary fibrosis. The research will utilize an aged murine model of idiopathic pulmonary...

This $149,948 Project Grant award from the National Heart Lung and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to investigate the role of p53 signaling and endothelial-to-mesenchymal transition in the development of radiation-induced coronary heart disease. The project will utilize human-induced pluripotent stem cell (iPSC) models and transgenic mouse models to map gene regulatory network perturbations across different cell types...

The National Heart, Lung, and Blood Institute (NHLBI) awarded a $374,100 project grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of California, San Diego (UCSD) to characterize the regulatory mechanisms of desmosomal protein expression in arrhythmogenic cardiomyopathy (ACM). The primary objectives of this 2-year project are to employ molecular and computational approaches to screen for differential transcriptomic and proteomic changes related to the...